tPA Administration in Patients on Plavix and Eliquis
tPA can be administered to patients on clopidogrel (Plavix) alone, but should NOT be given to patients currently taking apixaban (Eliquis) or other oral anticoagulants unless specific conditions are met.
Clopidogrel (Plavix) - Safe to Proceed
IV alteplase is recommended for patients taking antiplatelet drug combination therapy (including aspirin and clopidogrel) before stroke, as the benefit outweighs the probable increased risk of symptomatic intracranial hemorrhage 1. The 2018 AHA/ASA Guidelines explicitly state this as a Class I, Level B-NR recommendation, meaning you should proceed with thrombolysis in these patients.
Key Points for Antiplatelet Therapy:
- Single antiplatelet (Class I; LOE A) - definitely give tPA
- Dual antiplatelet including clopidogrel (Class I; LOE B-NR) - definitely give tPA
- There is a probable increased risk of symptomatic ICH, but clinical benefit still outweighs this risk 1
Apixaban (Eliquis) - Generally Contraindicated
Patients taking oral anticoagulants (OACs) are explicitly excluded from standard tPA eligibility 1. The 2018 guidelines state that IV alteplase in the 3-4.5 hour window is only recommended for patients "not taking any OACs."
Critical Caveats for NOAC Use:
However, emerging real-world evidence suggests nuance:
If you must consider tPA in a patient on apixaban:
Timing matters most: The median time from last NOAC dose to symptom onset in treated patients was 8 hours, with 55% occurring within 12 hours of last dose 2. Patients further from their last dose may have lower anticoagulant effect.
Laboratory testing is inadequate: Standard coagulation tests (PT/INR, aPTT) do not reliably detect NOAC activity. Sensitive tests like anti-Xa assays are needed but rarely available emergently 2.
Observed outcomes from registry data: Among 251 NOAC patients who received tPA (including 40 on apixaban), symptomatic ICH occurred in 4.8% versus 3.9% in non-anticoagulated patients (not statistically significant) 3. However, these were highly selected patients.
No reversal agent exists for apixaban in the acute setting (unlike dabigatran which has idarucizumab) 2.
Clinical Algorithm:
For a patient on BOTH Plavix and Eliquis:
- Do NOT give tPA - the oral anticoagulant is the limiting factor
- Consider mechanical thrombectomy instead, which is increasingly used regardless of antithrombotic status 4
- If considering tPA despite guidelines:
- Document time since last Eliquis dose (>24-48 hours may be safer per FDA labeling 5)
- Recognize you are operating outside standard guidelines
- Weigh severe stroke with poor prognosis against hemorrhage risk
- Consider this only in catastrophic strokes where thrombectomy is unavailable
Common Pitfall:
Do not confuse the Class I recommendation for dual antiplatelet therapy with permission to give tPA to patients on anticoagulants. The guidelines explicitly separate these categories - antiplatelets are acceptable, oral anticoagulants are not 1.
Bottom Line:
- Plavix alone or with aspirin: Give tPA (Class I recommendation)
- Eliquis: Do not give tPA (contraindication per guidelines)
- Both together: The anticoagulant is the deal-breaker - do not give tPA unless in extraordinary circumstances with full informed consent and documentation
The in vitro data actually shows apixaban does not enhance alteplase-induced thrombolysis 6, and current clinical practice considers thrombolysis contraindicated in anticoagulated patients despite emerging observational data suggesting it may be tolerated in highly selected cases 2, 3.